Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Key Highlights
- ➤792 LYMPHIR units purchased by U.S. wholesalers, up 120% quarter-over-quarter
- ➤950 LYMPHIR vials ordered by prescribing centers during fiscal Q4 2026
- ➤54 institutions ordered LYMPHIR, up from 44 as of August 14
- ➤Expanded commercial team reached nationwide coverage in August
- ➤Citius Oncology targets LYMPHIR formulary placement at 100 priority institutions by year-end
Expert Statements
Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology
“The fiscal fourth quarter showed continued institutional demand for LYMPHIR. Unit sales to wholesalers more than doubled as our expanded commercial team reached nationwide coverage in August”
Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology
“We are now more than halfway to our goal of having LYMPHIR on formulary at 100 priority institutions by calendar year-end.”
Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology
“As we enter fiscal 2027, we expect the momentum we built in the fourth quarter to carry forward, with growing institutional demand, deeper penetration into academic and community treatment centers, and continued sales growth as LYMPHIR becomes further established in CTCL.”
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 PR Newswire
CRANFORD, N.J., Oct. 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced preliminary, unaudited LYMPHIR(®) (denileukin diftitox-cxdl) unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026.
Get started
Create a free account to read the full story.